ODYY.OQBOdyssey Health, INC
10-Q: Odyssey Health Reports Q2 2024 Results, Highlights Asset Sale and Debt Restructuring
Sentiment:
Quarterly Report
Odyssey Health, Inc. reports a net income of $12.7 million for the six months ended January 31, 2024, driven by a significant gain from the sale of assets to Oragenics, Inc.
Capital raiseThe company's ability to continue as a going concern is dependent on raising additional capital.The company may obtain capital through issuances of debt or equity or entering into collaborative arrangements with corporate partners.The company is actively seeking additional financing to meet its obligations and execute its business plan.
Better than expectedThe company's net income was significantly better than expected due to a large gain from the sale of assets.
Summary
- Odyssey Health, Inc. reported a net income of $12.7 million for the six months ended January 31, 2024, compared to a net loss of $3.8 million for the same period last year.
- The company's financial turnaround was primarily due to a $16.4 million gain from the sale of assets to Oragenics, Inc.
- Operating expenses decreased, with research and development expenses down by 82% and general and administrative expenses down by 41% compared to the previous year.
- The company sold assets related to brain-related illnesses to Oragenics for $1 million in cash, 8 million shares of convertible Series F preferred stock, and the assumption of $325,672 in liabilities.
- Odyssey Health's cash position increased to $166,140 as of January 31, 2024, from $36,865 at the end of July 2023.
- The company continues to face a going concern issue due to recurring losses and negative cash flow, requiring additional capital to meet obligations.
- The company has restructured some of its debt, including extending maturity dates and converting debt into equity.
Sentiment
Score: 5
Explanation: The document presents a mixed picture. While the company achieved a significant net income due to an asset sale, it still faces substantial financial challenges, including a going concern warning and material weaknesses in internal controls. The positive financial results are largely non-recurring, and the company's future is highly dependent on its ability to raise additional capital.
Positives
- The company achieved a significant turnaround in net income due to the asset sale.
- Operating expenses were substantially reduced, indicating improved cost management.
- The company successfully restructured some of its debt, extending maturity dates and converting debt to equity.
- The company's cash position improved, providing some financial flexibility.
- The sale of assets to Oragenics generated a substantial gain and provided cash.
Negatives
- The company continues to operate at a loss from operations, indicating a lack of sustainable revenue generation.
- The company has a significant accumulated deficit of $47.4 million as of January 31, 2024.
- The company's auditors have raised substantial doubt about its ability to continue as a going concern.
- The company has material weaknesses in its internal control over financial reporting.
- The company is reliant on external financing to continue operations.
Risks
- The company's ability to continue as a going concern is dependent on raising additional capital.
- The company may be required to scale down or cease operations if additional financing is not obtained.
- The company's reliance on debt financing increases its liabilities and future cash commitments.
- The company's stock price could be negatively impacted by the material weaknesses in internal control over financial reporting.
- The company is subject to a lawsuit that could result in financial losses.
Future Outlook
The company expects to experience continuing operating losses and negative cash flows from operations for the foreseeable future. The company's continued existence depends on its ability to raise additional capital.
Management Comments
- The company plans to license, improve, and develop its products and identify and select distribution channels.
- The company intends to establish agreements with distributors to get products to market quickly and undertake and engage in direct marketing efforts.
- The company will engage third-party research and development firms to assist in developing its own products.
Industry Context
The company's shift in focus from brain-related illnesses to other medical products reflects a strategic pivot in response to market conditions and financial constraints. The sale of assets to Oragenics is a move to streamline operations and focus on core competencies. The company's reliance on external financing is common for early-stage medical device companies.
Comparison to Industry Standards
- The company's significant reduction in R&D spending is unusual for a biotech company, suggesting a shift away from active product development.
- The reliance on debt financing and the going concern warning are common for early-stage companies but indicate a high level of financial risk.
- The asset sale to Oragenics is a strategic move to generate cash, which is a common practice for companies facing financial difficulties.
- The company's net income is not indicative of operational success but rather a one-time gain from the sale of assets.
- The company's financial performance is significantly below industry standards for established medical device companies.
Legal Proceedings
- The company is a party to a lawsuit in Superior Court, Kent County in the State of Rhode Island, where a motion to dismiss has been entered and a hearing is scheduled for July 8, 2024.
Related Party Transactions
- The company has outstanding promissory notes with officers and directors.
- The company has amounts due to officers for reimbursement of expenses.
- The company has unpaid salary and bonus due to officers.
Stakeholder Impact
- Shareholders face significant risk due to the company's going concern status and reliance on external financing.
- Employees may be impacted by potential scaling down or cessation of operations.
- Customers and suppliers are not directly impacted at this stage as the company is not currently selling or marketing any products.
- Creditors face risk due to the company's financial instability and reliance on debt financing.
Next Steps
- The company needs to secure additional financing to continue operations.
- The company will focus on developing and commercializing its remaining medical products.
- The company will seek regulatory approvals for its products.
- The company will establish distribution agreements to bring products to market.
Key Dates
| Date | Description |
|---|---|
| 2021-08-01 | Date of Directors and Officers Promissory Notes. |
| 2021-12-21 | Date of Promissory Notes with directors and officers. |
| 2022-12-13 | Date of Securities Purchase Agreement with Mast Hill Fund, L.P. |
| 2023-06-13 | Date of Amendment No. 1 to the Securities Purchase Agreement with Mast Hill Fund, L.P. |
| 2023-07-07 | Date of $150,000 advance from accredited investor related to Note Purchase Agreement. |
| 2023-08-15 | Date of Note Purchase Agreement with two accredited investors. |
| 2023-08-28 | Date of $30,000 principal payment to LGH Investments, LLC. |
| 2023-10-04 | Date of Asset Sale Agreement with Oragenics, Inc. |
| 2023-10-19 | John Gandolfo, former director, exercised option to convert his convertible note. |
| 2023-11-01 | Date of Promissory Note Amendments with directors and officers. |
| 2023-12-11 | Odyssey Health received $500,000 from Oragenics upon stockholder approval for the sale of assets. |
| 2023-12-15 | Date of $50,000 principal payment to LGH Investments, LLC. |
| 2023-12-20 | ClearThink Capital Partners, LLC exercised option to convert their convertible note. |
| 2023-12-28 | Closing date of Asset Sale Agreement with Oragenics, Inc. |
| 2023-12-29 | Accredited investors provided notice to convert their Note Purchase Agreement. |
| 2023-12-30 | Date of Amendment No. 7 to Convertible Promissory Note with LGH Investments, LLC. |
| 2024-01-26 | Conversion of $528,767 of debt and accrued interest into 7,343,989 shares of common stock with accredited investors. |
| 2024-01-31 | Date of Promissory Note Amendments with directors and officers. |
| 2024-02-13 | Date of six-month promissory note with Jonathan Lutz. |
| 2024-03-13 | Date of Amendment No. 2 to the Securities Purchase Agreement with Mast Hill Fund, L.P. |
| 2024-03-14 | Mast Hill exercised a cashless warrant for 1,926,713 common stock shares. |
| 2024-03-22 | Date of outstanding shares of common stock. |
| 2024-06-28 | Oragenics restricted common stock becomes freely tradeable. |
| 2024-06-30 | Maturity date of convertible promissory note with LGH Investments, LLC. |
| 2024-07-08 | Notice of hearing in the Kent County Superior Court. |
| 2024-07-31 | Maturity date of Promissory Notes with directors and officers. |
| 2024-08-11 | Maturity date of promissory note with Jonathan Lutz. |
| 2024-08-15 | Maturity date of Note Purchase Agreement with two accredited investors. |
| 2024-09-13 | Amortization payment due to Mast Hill Fund, L.P. |
| 2024-12-13 | Maturity date of Mast Hill convertible promissory note. |
Keywords
asset sale, debt restructuring, net income, Oragenics, convertible debt, going concern, financial results, stock issuance, research and development, operating expenses
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.